Hu Di, Li Mengquan, Su Jing, Miao Keke, Qiu Xinguang
1 Department of Breast Disease Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China.
2 Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China.
Genet Test Mol Biomarkers. 2019 Mar;23(3):156-165. doi: 10.1089/gtmb.2018.0259. Epub 2019 Feb 26.
Increasing evidence links the abnormal expression of microRNAs and ATP-binding cassette subfamily C member 4 (ABCC4) with tumor development and progression, as well as with chemoresistance. Our aims were to determine the therapeutic potential of targeting both miR-124-3p and ABCC4 in breast cancer cells and to determine if duel targeting increased their sensitivity to chemotherapeutic drugs, in vitro.
The expression of the ABCC4 protein and miR-124-3p were detected, respectively, by immunohistochemical staining and quantitative real-time polymerase chain reaction in breast cancer tumor tissue, MCF-7 and MCF-7-ADR cell lines. Suppression of ABCC4 expression and miR-124-3p overexpression were performed in MCF-7-ADR cell lines. Western blot assays were used to detect expression of ABCC4 and permeability glycoprotein 1/multi-drug resistance protein 1 (P-gp) in cells. Cell Counting Kit-8, flow cytometry, transwell, and scratch assays were conducted to detect cell proliferation, cell cycle, invasion, and migration of cells.
We found that ABCC4 protein expression was significantly increased, while the miR-124-3p level was significantly decreased in breast cancer tissue and cell lines. Tumor size and clinical tumor node metastasis stage were significantly correlated with elevated expression of ABCC4 and decreased expression of miR-124-3p. Interestingly, ABCC4 expression was significantly increased in MCF-7-ADR cells, while miR-124-3p level was significantly decreased compared with MCF-7 cells. The inhibition of ABCC4 and miR-124-3p overexpression both led to a significant decrease in cell proliferation, invasion, and migration of MCF-7-ADR cells, and combination of suppression of ABCC4 with miR-124-3p overexpression had a synergistic inhibitory effect. Our results further demonstrated that inhibition of ABCC4 expression and overexpression of miR-124-3p significantly enhanced the sensitivity to adriamycin (ADR) in MCF-7-ADR cells, and that simultaneous dual-targeting of miR-124-3p and ABCC4 had a stronger promotive effect on the sensitivity to ADR in MCF-7-ADR cells. Moreover, western blot analysis showed that miR-124-3p overexpression significantly inhibited P-gp expression in MCF-7-ADR cells.
Our data demonstrate that the combination of downregulation of ABCC4 with overexpression of miR-124-3p significantly increased sensitivity to ADR in MCF-7-ADR cells. This finding suggests that similar dual targeting may serve as a means to enhance therapies for drug-resistant breast cancers.
越来越多的证据表明,微小RNA(miRNA)和ATP结合盒亚家族C成员4(ABCC4)的异常表达与肿瘤的发生、发展以及化疗耐药性有关。我们的目的是确定在乳腺癌细胞中同时靶向miR-124-3p和ABCC4的治疗潜力,并确定双重靶向是否能在体外增加它们对化疗药物的敏感性。
分别通过免疫组织化学染色和定量实时聚合酶链反应检测乳腺癌肿瘤组织、MCF-7和MCF-7-ADR细胞系中ABCC4蛋白和miR-124-3p的表达。在MCF-7-ADR细胞系中进行ABCC4表达的抑制和miR-124-3p的过表达。采用蛋白质免疫印迹法检测细胞中ABCC4和通透性糖蛋白1/多药耐药蛋白1(P-gp)的表达。使用细胞计数试剂盒-8、流式细胞术、Transwell和划痕试验检测细胞增殖、细胞周期、侵袭和迁移。
我们发现,乳腺癌组织和细胞系中ABCC4蛋白表达显著增加,而miR-124-3p水平显著降低。肿瘤大小和临床肿瘤淋巴结转移分期与ABCC4表达升高和miR-124-3p表达降低显著相关。有趣的是,与MCF-7细胞相比,MCF-7-ADR细胞中ABCC4表达显著增加,而miR-124-3p水平显著降低。抑制ABCC4和过表达miR-124-3p均导致MCF-7-ADR细胞的增殖、侵袭和迁移显著减少,抑制ABCC4与过表达miR-124-3p联合具有协同抑制作用。我们的结果进一步表明,抑制ABCC4表达和过表达miR-124-3p显著增强了MCF-7-ADR细胞对阿霉素(ADR)的敏感性,同时靶向miR-124-3p和ABCC4对MCF-7-ADR细胞对ADR的敏感性具有更强的促进作用。此外,蛋白质免疫印迹分析表明,过表达miR-124-3p显著抑制了MCF-7-ADR细胞中P-gp的表达。
我们的数据表明,下调ABCC4与过表达miR-124-3p相结合可显著增加MCF-7-ADR细胞对ADR的敏感性。这一发现表明,类似的双重靶向可能是增强耐药性乳腺癌治疗的一种手段。